The European Commission accused Sanofi of running a smear campaign against a rival flu vaccine, and it could change how every pharma company in Europe markets its products. Sanofi is already offering to play nice, but the implications go far beyond one company.
The Pharma Equivalent of a Smear Campaign
Imagine you own the most popular pizza shop in town. Business is great. Then a new spot opens across the street, and instead of making better pizza, you start telling customers the other place uses expired cheese.
That's essentially what the European Commission thinks Sanofi did with flu vaccines.
In late June 2026, the EU's top competition authority opened a formal antitrust investigation into Sanofi. The allegation: the French pharma giant ran a misleading marketing campaign that trashed a rival flu vaccine to protect its own market dominance. And the regulators aren't just asking politely. They raided Sanofi's offices back in September 2025 before making this formal.
Two Vaccines Walk Into a Doctor's Office
To understand the fight, you need to know the players. In Europe, there are really only two enhanced flu vaccines designed for vulnerable patients over 60: Sanofi's Efluelda (a high-dose shot) and Fluad from CSL Seqirus, an Australian company that uses a different approach called an adjuvant to boost immune response.
Think of it like Coke vs. Pepsi, except the market is smaller, the stakes involve elderly patients' health, and there's basically nobody else on the shelf. This near-duopoly means that when one company gains ground, the other loses it directly.
The Commission's preliminary view is that Sanofi holds a dominant position in the enhanced flu vaccine market in both France and Germany. That's important because EU law doesn't punish you for being dominant. It punishes you for abusing that dominance.
What Sanofi Allegedly Did
According to the Commission's preliminary assessment, Sanofi's marketing team targeted healthcare professionals in France and Germany with a campaign that did several questionable things.
First, the campaign allegedly portrayed Fluad as inferior to Efluelda, suggesting weaker evidence for its safety and effectiveness. Second, Sanofi reportedly , framing official guidance in a way that favored its own product. Third, specifically in Germany, the company allegedly implied that still surrounded Fluad's recommendation.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
misrepresented national vaccination recommendations
unresolved scientific objections
The kicker? The European Centre for Disease Control and national advisory groups in both countries had essentially concluded that both vaccines are recommended equally for elderly patients. So the marketing didn't just bend the truth; according to regulators, it contradicted the actual science.
The legal theory here is Article 102 TFEU, the EU rule that prohibits dominant companies from abusing their market power. The Commission believes Sanofi's campaign may have crossed the line from competitive promotion into anticompetitive disparagement.
Sanofi's "My Bad" Moment
Sanofi publicly maintains it has complied with all applicable laws, including competition law, and says it's cooperating fully with the investigation. But actions speak louder than press statements.
By July 8, 2026, Sanofi had already proposed commitments to resolve the case. Those commitments include publicly stating on its German and French websites that both Efluelda and Fluad are assessed and recommended equally for elderly patients. The company also offered to stop making negative comparative claims about Fluad. The Commission opened these proposed commitments to third-party feedback, with a deadline of August 21, 2026.
Offering commitments this quickly is the corporate equivalent of settling out of court. You don't necessarily admit wrongdoing, but you're clearly eager to make the problem go away. And there's good reason for that urgency: EU antitrust rules allow fines of up to 10% of global turnover if anticompetitive conduct is proven.
Why This Is Bigger Than One Flu Shot
This case could reshape how every pharma company in Europe talks about its competitors.
Historically, EU antitrust enforcement in pharma has focused on the usual suspects: price-fixing cartels, patent gaming to block generics, and excessive pricing. The Commission and national competition authorities racked up 29 antitrust decisions against pharmaceutical companies in the period 2009–2017, but most involved pricing or market-access tactics.
Marketing-as-antitrust-violation is newer territory. The closest precedent is the Commission's 2022 investigation into Vifor Pharma, which allegedly ran a disparagement campaign against a rival intravenous iron treatment. That case established that spreading misleading safety information about a competitor's product can constitute abuse of dominance.
The Sanofi probe takes this principle and applies it squarely to vaccines, a category where doctor recommendations (influenced heavily by marketing) directly determine which product patients receive. In vaccine markets, official guidance and physician perception aren't just factors in the purchase decision; they are the purchase decision.
If the Commission's theory holds, it means any dominant vaccine maker that selectively presents data or mischaracterizes official recommendations to undermine a competitor could face antitrust liability. That's a significant new constraint on commercial teams across the industry.
The Competitive Landscape Gets Interesting
The timing matters, too. CSL Seqirus withdrew its quadrivalent version of Fluad (Fluad Tetra) from European markets in February 2026 for commercial reasons, leaving only the trivalent version to compete against Efluelda. That withdrawal could have made the competitive dynamics even more lopsided, potentially making Sanofi's alleged campaign more damaging to what was already a weakened rival.
Meanwhile, GSK's flu vaccine sales declined in 2024, and the company doesn't really compete in the enhanced elderly segment at all. Its Fluarix Tetra plays in the standard-dose quadrivalent space, where competition is broader and less concentrated.
So for Europe's most vulnerable flu patients (those over 60 with risk factors), the choice remains essentially binary: Sanofi or CSL Seqirus. That's exactly why the Commission cares so much about how these two products are marketed.
What Happens Next
The Commission will review third-party feedback on Sanofi's proposed commitments through August. If the commitments are accepted, Sanofi avoids a fine but accepts binding restrictions on how it markets Efluelda versus Fluad going forward.
If they're rejected, or if feedback reveals the commitments don't go far enough, this could escalate into a full enforcement action with a formal statement of objections and potentially massive financial penalties.
Either way, the message to pharma is clear: in vaccine markets where you're dominant, your sales deck is now a compliance document. The days of aggressive comparative marketing without bulletproof scientific backing may be over, at least in the EU.
For Sanofi, the best-case scenario is a slap on the wrist and some awkward website disclaimers. The worst case? A precedent-setting fine and a playbook that every competitor in pharma will use to file complaints the next time a dominant player gets too creative with its marketing slides.
5 min read
Sarepta's Worst Week: Two Deaths, a Black Box, and 500 Pink Slips
Sarepta's Duchenne gene therapy Elevidys just got the FDA's most severe safety warning after fatal liver failures, while the company slashes 36% of its workforce and pivots away from gene therapy entirely. It's a brutal week that raises big questions about the future of the entire field.
